Trial Profile
A Phase 2, Randomised, Double Masked, Sham Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects With Non-proliferative Diabetic Retinopathy (NPDR)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2021
Price :
$35
*
At a glance
- Drugs Ocriplasmin (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms CIRCLE
- Sponsors Oxurion
- 22 Dec 2021 This trial has been completed in Belgium (Global end date: 18 Nov 2019).
- 07 Jan 2020 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 20 Dec 2019 This trial has been completed in Spain (Global End Date: 18 Nov 2019) according to European Clinical Trials Database record.